Radelumin is an advanced radiopharmaceutical product designed for diagnostic imaging, particularly in the detection of prostate-specific membrane antigen (PSMA) in patients. The injectable solutions of Radelumin are available in concentrations of 1300 MBq/ml and 2000 MBq/ml, using [18F]PSMA-1007 as the active compound. It plays a critical role in enhancing the precision of PET scans by providing clear imagery of PSMA-positive tissues which are often indicative of prostate cancer. The product is intended for healthcare professionals with specialized training in nuclear medicine. The high-level radioactivity of Radelumin highlights its powerful capabilities for in-depth diagnostic applications, while also necessitating stringent safety protocols during handling and administration. Detailed educational materials and support are available to ensure optimal use and compliance with regulatory standards.
